Usefulness of Measuring Fractional Exhaled Nitric Oxide (FeNO) In Various Respiratory Diseases

H. Nagase, T. Toda, A. Kamiyama, Y. Nakase, N. Sugimoto, H. Yoshihara, M. Kuramochi, H. Tashimo, H. Arai, M. Yamaguchi, N. Suzuki, K. Ohta

Author address: 

Teikyo University, Tokyo, JAPAN.


RATIONALE: The clinical usefulness of measuring FeNO in various respiratory diseases other than asthma has not been fully established. The aim of this study is to validate the disease specificity of FeNO in asthma and to identify the respiratory disease in which measuring FeNO is useful. METHODS and RESULTS: FeNO (ppb) was measured by NIOX MINO and result was as follows. Stable BA using ICS (n=57, sBA, 48.0±5.3), unstable BA using ICS (n=15, usBA, 73.7±10.3), untreated BA (n=15, utBA, 72.3±10.3), COPD (n=17, 23.8±9.7), sleep apnea syndrome (SAS, n=15, 22.9±10.3), interstitial pneumonia (IP, n=10, 21.2±12.6), and bronchiectasis (BE, n=11, 32.7±12.0). FeNO was significantly lower in COPD, IP, SAS as compared to utBA or usBA. The cut-off level of FeNO to distinguish utBA and non-BA diseases was 45 ppb. Among 53 non-BA cases, only one COPD and two BE patients showed FeNO>45 ppb and sputum eosinophil was positive in all these cases. In contrast, when FeNO was

abstract No: 


Full conference title: 

American Academy of Allergy Asthma & Immunology
    • AAAAI 2011 (67th)